Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)’s share price rose 2.2% during trading on Friday . The company traded as high as $90.86 and last traded at $90.07, with a volume of 741,126 shares. The stock had previously closed at $88.15.

VRTX has been the topic of a number of recent analyst reports. Robert W. Baird reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Monday, April 25th. Jefferies Group reaffirmed a “buy” rating and set a $103.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, June 17th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, March 23rd. Goldman Sachs Group Inc. cut their price target on Vertex Pharmaceuticals from $129.00 to $106.00 and set a “buy” rating on the stock in a research note on Wednesday, March 23rd. Finally, Credit Suisse Group AG reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, June 16th. Eight equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $125.11.

The stock’s 50 day moving average price is $89.29 and its 200-day moving average price is $89.49. The firm’s market capitalization is $22.31 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, April 27th. The pharmaceutical company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by $0.20. The business earned $398.10 million during the quarter, compared to analysts’ expectations of $439.94 million. During the same period in the prior year, the company earned ($0.62) earnings per share. The business’s quarterly revenue was up 187.4% on a year-over-year basis. Equities analysts anticipate that Vertex Pharmaceuticals Inc. will post $1.03 EPS for the current year.

In other news, Director Joshua S. Boger sold 5,130 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $94.95, for a total value of $487,093.50. Following the transaction, the director now owns 273,355 shares in the company, valued at approximately $25,955,057.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Paul M. Silva sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $87.63, for a total value of $262,890.00. Following the completion of the transaction, the senior vice president now owns 15,950 shares in the company, valued at approximately $1,397,698.50. The disclosure for this sale can be found here.

Several institutional investors have made changes to their positions in the company. Employees Retirement System of Texas increased its position in shares of Vertex Pharmaceuticals by 41.5% in the fourth quarter. Employees Retirement System of Texas now owns 92,000 shares of the pharmaceutical company’s stock worth $11,576,000 after buying an additional 27,000 shares during the last quarter. Greenwood Capital Associates LLC increased its position in shares of Vertex Pharmaceuticals by 0.7% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,768 shares of the pharmaceutical company’s stock worth $1,355,000 after buying an additional 80 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth $2,240,000. Marshall Wace LLP increased its position in shares of Vertex Pharmaceuticals by 158.6% in the fourth quarter. Marshall Wace LLP now owns 241,824 shares of the pharmaceutical company’s stock worth $30,428,000 after buying an additional 148,314 shares during the last quarter. Finally, Cibc World Markets Corp increased its position in shares of Vertex Pharmaceuticals by 22.2% in the fourth quarter. Cibc World Markets Corp now owns 20,690 shares of the pharmaceutical company’s stock worth $2,603,000 after buying an additional 3,760 shares during the last quarter.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.